Tag: Goal

Posted on

AstraZeneca asthma drug hits goal, to enter competitive market – Reuters


Reuters

AstraZeneca asthma drug hits goal, to enter competitive market
Reuters
L) drive to rebuild its portfolio of new medicines received a boost with positive results for an experimental biotech drug for severe asthma that the company previously flagged as a potential $2 billion-a-year seller. Benralizumab, which is likely to …
AstraZeneca: Asthma drug trial results positiveMarketWatch
Astrazeneca Reports Results On Benralizumab Phase III Programme In Severe AsthmaNasdaq
TOP NEWS: AstraZeneca Gets Positive Benralizumab Phase III Trial ResultsLondon South East (registration) (blog)

all 6 news articles »

View full post on asthma – Google News

Posted on

Wing®, the First Way to Prevent Asthma Attacks, Exceeds $50K Funding Goal on … – The Edwardsville Intelligencer

Wing®, the First Way to Prevent Asthma Attacks, Exceeds $50K Funding Goal on …
The Edwardsville Intelligencer
“Running this campaign has provided people with asthma and other respiratory conditions the opportunity to be the first to get Wing, and help spread awareness about the impact of these overlooked conditions,” Co-founder Abby Cohen said. “The feedback …

and more »

View full post on asthma – Google News

Posted on

Array Biopharma’s new asthma drug meets goal of improved lung function – Denver Post

Array Biopharma's new asthma drug meets goal of improved lung function
Denver Post
Array Biopharma Inc. said Tuesday, one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose 12.7 percent, or 71 cents, to $6.27 in morning …
Array BioPharma: Study Shows Asthma Candidate ARRY-502 Improves Lung …Wall Street Journal
Array BioPharma scores midstage success for asthma drugFierceBiotech
Array Shares Climb After Asthma Drug Shows Positive Phase 2 ResultsXconomy
NASDAQ –TheStreet.com –KFGO
all 10 news articles »

View full post on asthma – Google News

Posted on

Targacept: Drug missed goal due to analysis error – BusinessWeek


Citybizlist

Targacept: Drug missed goal due to analysis error
BusinessWeek
Drug developer Targacept Inc. said Tuesday that further analysis showed an experimental asthma treatment failed one one of its goals in a clinical trial, contrary to what the company previously reported. Targacept shares lost 59 cents, or 12.2 percent, …
Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of …MarketWatch (press release)
Targacept reports error in asthma studyTriad Business Journal
Targacept loses big shareholder, finds error in previous studyWinston-Salem Journal
Wall Street Journal
all 22 news articles »

View full post on asthma – Google News